摘要
铁死亡抑制蛋白1(FSP1)是新近被证实的铁死亡抑制因子,与乳腺癌、卵巢癌、肺癌、肝细胞癌、黑色素瘤、淋巴瘤、白血病、铜耐受、重症急性胰腺炎、糖尿病等疾病的发生发展密切相关。有研究发现,FSP1基于其氨基酸系列C末端片段、核易位、过表达等因素诱导非caspase依赖性的细胞凋亡,并可通过FSP1-CoQ_(10)-NAD(P)H途径、平行于经典的谷胱甘肽(GSH)-GPX4途径使细胞免于铁死亡,在细胞生命活动中发挥"双刃剑"的作用。该文综述目前FSP1在人类疾病中作用机制的研究进展,以期为疾病防治提供新的靶标。
Ferroptosis suppressor protein 1(FSP1),confirmed as a ferroptosis-resistant factor recently,plays a key role in the oncogenesis and progress of human diseases,such as breast cancer,ovarian cancer,lung cancer,hepatocellular carcinoma,melanoma,lymphoma,leukemia,copper resistance,severe acute pancreatitis,and diabetes.FSP1 is regarded as a double-edged sword according to previous studies.Mechanically,FSP1 triggers caspase-independent apoptosis via its C-terminal fragments,nuclear translocation,or over-expression,and inhibits ferroptosis through FSP1-CoQ10-NAD(P)H axis,being independent of the glutathione(GSH)-GPX4 axis.The research progress in action mechanism of FSP1 in human diseases is briefly described in this review for providing novel preventative and therapeutic target molecules for human diseases.
作者
陆会平
党裔武
陈罡
Lu Hui-Ping;Dang Yi-Wu;Chen Gang(Department of Pathology,the First Affiliated Hospital of Guangxi Medical University,Nanning 530021,China)
出处
《解放军医学杂志》
CAS
CSCD
北大核心
2021年第7期731-736,共6页
Medical Journal of Chinese People's Liberation Army
基金
广西研究生教育创新计划项目(YCBZ2020045,JGY2019050)
广西医疗卫生适宜技术开发与推广应用项目(S2020031)。
